Leerink Swann reiterated their buy rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research note issued to investors on Wednesday morning. They currently have a $530.00 target price on the biopharmaceutical company’s stock.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Other analysts have also recently issued reports about the company. Vetr cut Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $419.76 target price for the company. in a research note on Monday, July 11th. Sanford C. Bernstein reissued a buy rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 30th. Citigroup Inc. reissued a buy rating and set a $470.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 23rd. Brean Capital reissued a buy rating and set a $489.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Roth Capital reissued a buy rating and set a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $471.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.10% during mid-day trading on Wednesday, reaching $406.92. 44,092 shares of the company’s stock were exchanged. The company has a market cap of $42.58 billion, a PE ratio of 63.48 and a beta of 1.24. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59. The stock has a 50-day moving average price of $407.89 and a 200 day moving average price of $389.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. The company earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. Regeneron Pharmaceuticals’s revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.89 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post $10.93 earnings per share for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now directly owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares during the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares during the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.